APA (7th ed.) Citation

Wainwright, C., McColley, S., McNally, P., Powers, M., Ratjen, F., Rayment, J., . . . Davies, J. (2023). 133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study. Journal of Cystic Fibrosis, 22, S70. https://doi.org/10.1016/S1569-1993(23)01066-4

Chicago Style (17th ed.) Citation

Wainwright, C., et al. "133 Long-term Safety and Efficacy of Elexacaftor-tezacaftor-ivacaftor in Children Aged 6 and Older with Cystic Fibrosis and at Least One F508del Allele: 144-week Results of an Open-label Extension Study." Journal of Cystic Fibrosis 22 (2023): S70. https://doi.org/10.1016/S1569-1993(23)01066-4.

MLA (9th ed.) Citation

Wainwright, C., et al. "133 Long-term Safety and Efficacy of Elexacaftor-tezacaftor-ivacaftor in Children Aged 6 and Older with Cystic Fibrosis and at Least One F508del Allele: 144-week Results of an Open-label Extension Study." Journal of Cystic Fibrosis, vol. 22, 2023, p. S70, https://doi.org/10.1016/S1569-1993(23)01066-4.